Stephen Hill, BM, BCh, MA, FRCS
President and Chief Executive Officer,
Solvay Pharmaceuticals
As president and chief executive officer (CEO) of Solvay Pharmaceuticals, Inc., Dr. Stephen Hill focuses on expanding the company’s presence in the United States through aggressive strategies to grow the current business together with pipeline development and acquisitions. He is a member of the corporation’s board of directors and management committee and an officer of the corporation. In addition, Hill serves as president and CEO of all Solvay Pharmaceuticals subsidiaries including Unimed Pharmaceuticals, LLC,
Organics L.L.C. and Solvay Biologicals, LLC.
Hill served as president and CEO of biotechnology firm ArQule, Inc. from 1999-2008. Prior to his position at ArQule, Hill was the Head of Global Drug Development at F. Hoffmann-La Roche Ltd. from 1997-1999. He joined Roche in 1989 as Medical Adviser to Roche Products in the United Kingdom and held several senior positions there that included U.K. Medical Director and Head of International Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland. Hill is a Fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College at Oxford University.
Hill currently serves on the board of directors of the Pharmaceutical Research and Manufacturers Association of America and Georgia Bio.
Solvay Pharmaceuticals, Inc., of Marietta, Georgia is the U.S. subsidiary of Solvay Pharmaceuticals.
For more information, visit www.solvaypharmaceuticals-us.com.
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology, and men’s and women’s health. Its 2007 sales were EUR 2.6 billion and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.
SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 28,000 people in 50 countries.
In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at www.solvay.com
